Translating Oocyte Biology Discoveries To New Clinical Practices
Funder
National Health and Medical Research Council
Funding Amount
$772,605.00
Summary
A/Professor Gilchrist is a reproductive biologist studying factors that regulate the intrinsic quality of unfertilised eggs. He has produced and patented the use of unique growth factors produced by the egg that enhance egg quality in women. Bringing together industry and a world-leading clinic, he is developing new forms of hormone-free infertility treatment which he will take to clinical practice over the next 5 years.
Life-saving chemo/radio-therapy commonly renders women and girls who survivor cancer infertile or sterile. We have discovered a new means of preserving the fertility of female mice exposed to chemo/radio therapy. In this project we will apply these advances to human ovarian tissue/eggs for the first time. We have access to these rare tissues for research purposes. This project will develop new approaches to fertility preservation for cancer survivors.
Is Calcium part of the mechanism used in glucose signalling in embryogenesis. A vital stage in the development of the embryo is formation of the blastocyst about 4 days after conception. For this to happen the embryo must receive glucose from the mother. We believe that rather being used by the embryo to generate energy, this glucose acts as a signal to switch on the developmental pathway leading to blastocyst formation. Without this signal there is no blastocyst and the pregnancy fails. The pr ....Is Calcium part of the mechanism used in glucose signalling in embryogenesis. A vital stage in the development of the embryo is formation of the blastocyst about 4 days after conception. For this to happen the embryo must receive glucose from the mother. We believe that rather being used by the embryo to generate energy, this glucose acts as a signal to switch on the developmental pathway leading to blastocyst formation. Without this signal there is no blastocyst and the pregnancy fails. The project investigates this signal mechanism. The results will advance understanding of the mechanisms regulating development and in particular link the mother's nutritive status to her fertility during very early pregnancy.Read moreRead less
Exploitation Of Unique Growth Factors To Develop New Products For Infertility Treatment
Funder
National Health and Medical Research Council
Funding Amount
$132,525.00
Summary
Infertility comes at an enormous social and financial cost to Australian society; infertility is a major psychological burden on young couples and the technologies used to treat infertility, such as in vitro fertilisation (IVF), require expensive drugs to stimulate the ovary. The cost of these drugs to Medicare is expected to exceed $100 million p.a. over the next decade. A reproductive technology, which has always shown great potential to elevate some of this burden, is oocyte (egg) in vitro ma ....Infertility comes at an enormous social and financial cost to Australian society; infertility is a major psychological burden on young couples and the technologies used to treat infertility, such as in vitro fertilisation (IVF), require expensive drugs to stimulate the ovary. The cost of these drugs to Medicare is expected to exceed $100 million p.a. over the next decade. A reproductive technology, which has always shown great potential to elevate some of this burden, is oocyte (egg) in vitro maturation (IVM), which drastically reduces the use-cost of drugs and the stress to patients. However, oocyte IVM has been slow to live up to its potential and the technology is still not in widespread clinical practice, mainly due to disappointing success rates in women. We have been studying oocyte IVM in animals for many years, and have recently made a significant technological breakthrough, improving success rates by ~50%. In this field, a 50% increase in efficiency is substantial and has significant clinical and commercial application. Currently, we are the only group worldwide with this technology. Over the course of this 2-year project we will conduct follow-up experiments to refine this discovery and investigate the feasibility of using this approach to treat human infertility. We are already in negotiations with two medical device manufacturers to licence this technology. We expect that this project will lead to a series of products and technologies that will enter a clinical trial for the treatment of infertility within 2-3 years.Read moreRead less
Development Of Engineered Novel Growth Factors For Infertility Treatment
Funder
National Health and Medical Research Council
Funding Amount
$410,439.00
Summary
Infertility comes at an enormous social and financial cost to Australian society. The aim of this proposal is to improve the success rate of an innovative technology that matures eggs in the laboratory and so eliminates the need for the hormones normally used in IVF. To achieve this a newly discovered egg-secreted protein first has to be produced in the laboratory.
Discovery Early Career Researcher Award - Grant ID: DE120100796
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Androgens and ovarian function. This innovative project aims to identify the role androgens play in the complex processes required for successful ovarian follicle development and ovulation. The project aims to identify androgen regulated pathways that orchestrate follicle development, which will have significance in the control of fertility and the advancement of reproductive technologies.
Discovery Early Career Researcher Award - Grant ID: DE120100304
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Biomimetic systems for species preservation and fertility restoration. Using a novel 3-D culture system the project will examine the biomechanics of ovary follicle and egg development in vitro, generating new knowledge with directly translatable research outcomes. In vitro egg production has implications for human fertility and threatened species preservation, significantly benefitting health and biodiversity in Australia.
Dr Gilchrist is a reproductive biologist studying factors that regulate the intrinsic quality of unfertilised eggs. He has developed a new form of hormone-free infertility treatment which he will test in a clinical trial over the next 5 years.